NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)

The NIAID New Innovator Awards (DP2 Clinical Trial Not Allowed) is a funding opportunity from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This award supports early-stage investigators (ESIs) who propose innovative and high-impact research that may not yet have substantial preliminary data but has the potential to test scientific paradigms or advance new concepts in biomedical research within NIAID's priority areas. The DP2 mechanism is designed to encourage creative approaches to major scientific challenges, particularly where traditional funding mechanisms may be less suitable due to the early-stage or high-risk nature of the work. This opportunity targets postdoctoral candidates, individuals in non-independent positions, and newly independent investigators. Eligible applicants must hold a research or clinical doctorate (e.g., PhD, MD) and have ESI status, meaning they completed their terminal degree within the past 10 years and have not been a principal investigator on a substantial independent NIH research award. Postdoctoral or non-independent investigators must transition to a faculty position at a U.S.-based institution within one year of receiving the award. Newly independent applicants must be within the first year of a faculty position at the time of application. The award aims to support research ideas that significantly differ from the investigator’s current work or postdoctoral training, promoting scientific independence. The NIAID New Innovator Award provides up to $300,000 in direct costs per year for a maximum of five years. Applications should not propose clinical trials, as this mechanism does not fund them. The proposed research must align with NIAID's mission to conduct and support research related to infectious, immunologic, and allergic diseases. Applicants are encouraged to pursue novel, interdisciplinary approaches that may challenge current scientific paradigms, leverage unexpected collaborations, or introduce new methodologies. Applications are expected to focus on the significance and potential impact of the proposed work, along with its creativity and innovation. While preliminary data is not required, a strong rationale for the feasibility and potential success of the research is essential. The review process will evaluate the research’s potential to expand the applicant’s research scope and promote their growth as an independent investigator. Emphasis will be placed on the applicant’s qualifications, including their contributions to the field, originality, and potential for scientific leadership. Eligible institutions include higher education institutions, public and private nonprofits, and other organizations, but non-domestic (non-U.S.) entities are not eligible to apply. Applicants must ensure they complete necessary registrations with the System for Award Management (SAM), eRA Commons, and Grants.gov before submission. Applications are submitted through NIH ASSIST, institutional system-to-system solutions, or Grants.gov Workspace. Applications are due annually in October, with the earliest start date being July of the following year. Prospective applicants are encouraged to submit a letter of intent 30 days prior to the application due date, although this step is optional. The NIAID emphasizes the importance of adhering strictly to the application guidelines provided in the SF424 (R&R) Application Guide and any program-specific instructions to avoid delays or disqualification. Recipients of this award are required to participate in two program meetings during the project period, which will be held in the Bethesda, Maryland area. These meetings aim to foster collaboration, discuss progress, and explore new research directions. Finally, NIH encourages applications from individuals of diverse backgrounds, including those from underrepresented racial and ethnic groups, women, and individuals with disabilities.